Financing channel feed – Endpoints News

Financing channel feed

BioNTech bets on difficult STING field via small molecule pact with a Polish biotech

3 years ago

Lundbeck-partnered preclinical biotech nabs Series A from AstraZeneca

3 years ago

Cajal Neuroscience launches with $96M Series A, tackling Alzheimer's and Parkinson's

3 years ago

San Diego biotech lands $120M to launch a slate of trials in neurosensory disorders

3 years ago

Lilly joins in expanded Series A round for BeiGene-partnered mRNA biotech

3 years ago

Scoop: Versant, NEA launch new biotech helmed by ex-CEO of protein degrader C4 Therapeutics

3 years ago

German biotech CatalYm raises $50M to flip weight loss target for cancer

3 years ago

Simulations for experiments: Bayer-backed startup lands $20M to test out its tech

3 years ago

Six-person ALS biotech wants to go public — but it’s also pivoting from earlier plans

3 years ago

With the clinic in sight, Greg Verdine's startup bags $178M for new class of targeted therapies

3 years ago

Plexxikon vets kick off new drug discovery outfit — with old assets and new target

3 years ago

European protein software startup Cradle launches with backing from Lyft, Twist CEOs

3 years ago

Emergent scores a DoD award to evaluate its chikungunya vaccine in the field

3 years ago

Tenaya bags $75M from stock sale as it prepares to put a gene therapy for heart disease into the clinic

3 years ago

Scorpion Capital goes after Twist Bioscience as latest synbio target, comparing biotech to Theranos

3 years ago

Following ASCO showing, Bert Vogelstein’s latest startup launches into recurrent cancer detection

3 years ago

A rare biotech IPO lands on Nasdaq, boosted by RA Capital and a former Eli Lilly drug

3 years ago

Can an oncolytic virus therapy challenge the standard of care in bladder cancer? CG Oncology has $120M to find out

3 years ago

The crew that sold its lead IL-2 program to Roche is back with $93M to work on more next-gen I/O drugs

3 years ago

Roche doubles down on Jnana's drug discovery platform, kicking off second deal with $50M cash — while biotech bags $107M

3 years ago

RA Capital jumps aboard nine-figure round for the endocrine biotech co-founded by Humalog inventor

3 years ago

Metabolics biotech secures humble Series A from big-name investors

3 years ago

Biohaven claims $300M+ public offering as company charts new journey after Pfizer buyout

3 years ago

Oral alternative to eye injections? Novo backs startup’s big plan to repurpose shelved drug

3 years ago

First page Previous page 43 44 454647 48 49 Next page Last page